Pharmaceutical Research Center This application seeks to continue the evolution of the Pharmaceutical Research Center at Florida A&M University (FAMU). The previously funded targeted research activities have demonstrated productivity and resulted in significant discoveries that have led to the award of several patents and additional pending discoveries. Based on the evaluation of the current research infrastructure and the strategic needs of the program, it is proposed to transition the targeted activities into the development of Core research facilities. The main objective of the current application is to build the infrastructure of the research program towards more understanding of the mechanistic details of the molecular system. This RCMI center will focus efforts on approaches, i.e., gene expression analysis, proteomics, PCR analysis, gene delivery systems and DNA microarray techniques. The establishment of Core facilities in the areas of molecular neurobiology, cellular imaging, neurochemistry/receptors, flow cytometery and nanomedicine will increase our abilities to understand the mechanistic details of the molecular system and to provide greater insights into how the different molecular are modulated under disease and adverse conditions. The Pharmaceutical Research Center will consist of a research administrative component coupled with four (4) core service delivery facilities. The administrative component will continue to provide pre- and post- award assistance, coordinate Ithe activities of the external and internal advisory committee, provide scientific seminars and grants workshops, coordinate a new structured mentoring program, facilitate an extensive external evaluation of program outcomes, assist in faculty development, hire a research faculty member and market and conduct an on-site grants management workshop and the annual RCMI R01 Scientist Seminar Series. Specif aim one (1) is to transition the program from the current research programs in neuroscience, drug delivery, and molecular biology to research cores focusing on Neurodegeneration research, Nanomedicine research, drug discovery and biotechnology: pathways to disease prevention and therapy. Through this network of Core facilities, the Pharmaceutical Research Center will foster inter- and inter-disciplinary research.
Aim two (2) is to increase research investigators capabilities and competitiveness to receive four (4) investigators initiated grants.
Aim three (3) is to assure the completion of program objectives and outcomes through a comprehensive formative and summative evaluation process.
Aim four (4) is to address health disparities through research emphasis on those conditions that adversely impact disadvantaged populations and produce additional minority scientists who will address disparities. This RCMI Program has been transformational at FAMU. Ensuring translational research is at the forefront of the proposed research activities as we seek to accelerate the utilization of our biomedical discoveries. The College's motto is """"""""Funding Cures and Saving Lives.""""""""

Agency
National Institute of Health (NIH)
Institute
National Institute on Minority Health and Health Disparities (NIMHD)
Type
Research Centers in Minority Institutions Award (G12)
Project #
8G12MD007582-28
Application #
8281414
Study Section
Special Emphasis Panel (ZRR1-RI-3 (01))
Program Officer
Mcclure, Shelia A
Project Start
1997-08-01
Project End
2013-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
28
Fiscal Year
2012
Total Cost
$2,340,738
Indirect Cost
$827,604
Name
Florida Agricultural and Mechanical University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
623751831
City
Tallahassee
State
FL
Country
United States
Zip Code
32307
Mochona, Bereket; Qi, Xin; Euynni, Suresh et al. (2016) Design and evaluation of novel oxadiazole derivatives as potential prostate cancer agents. Bioorg Med Chem Lett 26:2847-51
Zarmouh, Najla O; Messeha, Samia S; Elshami, Faisel M et al. (2016) Evaluation of the Isoflavone Genistein as Reversible Human Monoamine Oxidase-A and -B Inhibitor. Evid Based Complement Alternat Med 2016:1423052
Diaby, Vakaramoko; Adunlin, Georges; Ali, Askal A et al. (2016) Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat 160:187-196
Odewumi, Caroline O; Latinwo, Lekan M; Ruden, Michael L et al. (2016) Modulation of cytokines and chemokines expression by NAC in cadmium chloride treated human lung cells. Environ Toxicol 31:1612-1619
Diaby, Vakaramoko; Ali, Askal A; Adunlin, Georges et al. (2016) Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. Curr Med Res Opin 32:991-6
Cobourne-Duval, Makini K; Taka, Equar; Mendonca, Patricia et al. (2016) The Antioxidant Effects of Thymoquinone in Activated BV-2 Murine Microglial Cells. Neurochem Res 41:3227-3238
Tawk, Rima; Abner, Adrian; Ashford, Alicestine et al. (2016) Differences in Colorectal Cancer Outcomes by Race and Insurance. Int J Environ Res Public Health 13:ijerph13010048
Williams, Marlon D; Nguyen, Thu; Carriere, Patrick P et al. (2016) Protein Kinase CK2 Expression Predicts Relapse Survival in ERα Dependent Breast Cancer, and Modulates ERα Expression in Vitro. Int J Environ Res Public Health 13:ijerph13010036
Williams, Henry N; Lymperopoulou, Despoina S; Athar, Rana et al. (2016) Halobacteriovorax, an underestimated predator on bacteria: potential impact relative to viruses on bacterial mortality. ISME J 10:491-9
Mazzio, Elizabeth A; Li, Nan; Bauer, David et al. (2016) Natural product HTP screening for antibacterial (E.coli 0157:H7) and anti-inflammatory agents in (LPS from E. coli O111:B4) activated macrophages and microglial cells; focus on sepsis. BMC Complement Altern Med 16:467

Showing the most recent 10 out of 123 publications